Evidence map›Paper›PMID 42370175›Full record

ArticleTheranostics2026

Multimodal imaging-guided NIR-II photo-gas nanoplatform amplifies PD-1 blockade for synergistic TNBC therapy.

Linlin Song, Meixu Chen, Huiling Wang, Xin Wang, Tianyue Xu, Heqing Zhang, Shuwen Ran, Liwen Huang, Yingying Ma, Zhihui Liu and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Linlin SongDepartment of Medical Ultrasound, West China Hospital, Sichuan University, Chengdu, Sichuan, P. R. China, 610041.
Meixu ChenInstitute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, P. R. China, 610041.
Huiling WangInstitute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, P. R. China, 610041.
Xin WangInstitute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, P. R. China, 610041.
Tianyue XuInstitute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, P. R. China, 610041.
Heqing ZhangDepartment of Medical Ultrasound, West China Hospital, Sichuan University, Chengdu, Sichuan, P. R. China, 610041.
Shuwen RanInstitute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, P. R. China, 610041.
Liwen HuangInstitute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, P. R. China, 610041.
Yingying MaInstitute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, P. R. China, 610041.
Zhihui LiuInstitute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, P. R. China, 610041.
Zihan XuInstitute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, P. R. China, 610041.
Yujie ZhaoInstitute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, P. R. China, 610041.
Zichang LiuInstitute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, P. R. China, 610041.
Yong LuoDepartment of Oncology, Yingshan County People's Hospital, Nanchong, Sichuan, P. R. China, 637000.
Xiujun YuDepartment of Oncology, Yingshan County People's Hospital, Nanchong, Sichuan, P. R. China, 637000.
Yulan PengDepartment of Medical Ultrasound, West China Hospital, Sichuan University, Chengdu, Sichuan, P. R. China, 610041.
Hubing ShiInstitute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, P. R. China, 610041.
Jing JingInstitute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, P. R. China, 610041.
Xiujing HeInstitute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, P. R. China, 610041.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: Triple-negative breast cancer (TNBC) remains one of the most aggressive subtypes due to its poor immunogenicity and resistance to systemic therapies. Methods: Here, we report a multifunctional NIR-II light-triggered theranostic nanoplatform, termed LQPO, that integrates liposome, Ti Results: Upon NIR-II irradiation, LQPO produced strong photothermal and photoacoustic signals for real-time photoacoustic (PA) and contrast-enhanced ultrasound (CEUS) imaging, accompanied by vaporization of the PFH core and burst release of ozone. This spatiotemporally coordinated cascade induced potent oxidative stress and hyperthermia, synergistically driving GSDME-dependent pyroptosis and immunogenic cell death (ICD). The resulting "in situ vaccination" effect remodeled the tumor immune microenvironment and primed tumors for PD-1 blockade therapy. Conclusions: Overall, this study establishes a single-laser-activated nanoplatform that unifies real-time multimodal imaging and photo-gas synergistic therapy, and converts localized treatment into a systemic antitumor immune response upon integration with checkpoint inhibition.

Indexed as

Immune Checkpoint InhibitorsNanoparticlesProgrammed Cell Death 1 ReceptorTriple Negative Breast NeoplasmsAnimalsAntibodiesCell Line, TumorFemaleFluorocarbonsHumansInfrared RaysLiposomesMiceMice, Inbred BALB COxidation-ReductionOzoneAntibodiesFluorocarbonsImmune Checkpoint InhibitorsLiposomesOzoneperflexaneProgrammed Cell Death 1 ReceptorTitaniumtitanium carbidegas therapyimmune checkpoint blockadephotothermal therapyquantum dotstheranostic nanoplatform

Identifiers

PMID42370175
PMCPMC13295768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.